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BACKGROUND: Two noninferiority, randomized,
controlled trials were conducted in parallel comparing the
safety and efficacy of platelets treated with Intercept or
Mirasol pathogen-reduction technologies versus
standard platelets.
STUDY DESIGN AND METHODS: The primary
endpoint was the percentage of hematology patientswho
developedWorld Health Organization Grade 2 or greater
bleeding. A noninferiority margin of 11% was chosen based
on expected Grade 2 or greater bleeding in 20% of controls.
The study was closed for financial restrictions before reaching
the planned sample size of 828 patients, and an intention-to-
treat analysis was conducted on 424 evaluable patients.
RESULTS: In the Intercept trial (113 treated vs. 115 control
patients), the absolute risk difference in Grade 2 or greater
bleeding was 6.1%, with an upper one-sided 97.5%
confidence limit of 19.2%. The absolute risk difference in the
Mirasol trial (99 treated vs. 97 control patients) was 4.1%, and
the upper one-sided 97.5% confidence limit was 18.4%.
Neither absolute risk differencewas statistically significant. In
both trials, posttransfusion platelet count incrementswere
significantly lower in treated versus control patients. Mean
blood component use in treated patients versus controls was
54% higher (95% confidence interval, 36%-74%; Intercept)
and 34% higher (95% confidence interval, 16%-54%;
Mirasol) for platelets and 23% higher (95% confidence
interval, 8%-39%; Intercept) and 32% higher (95%
confidence interval, 10%-57%;Mirasol) for red blood cells.
Unexpected reactions and adverse eventswere not reported.
Mortality did not differ significantly between treated and
control patients.
CONCLUSION: Although conclusions on noninferiority
could not be drawn due to low statistical power, the study
provides additional information on the safety and efficacy
of pathogen-reduced platelets treated with two
commercial pathogen-reduction technologies.
ABBREVIATIONS:: AML 5 acute myeloid leukemia; ITT 5
intention to treat; PP 5 per protocol; PR 5 pathogen
reduction; RCT(s) 5 randomized controlled trial(s); UCL 5
upper one-sided 97.5% confidence limit.
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A
lthough it is extremely safe, platelet transfusion
carries measurable risks of adverse events,
including pathogen transmission, alloimmuni-
zation to human leukocyte antigens (HLAs), and
transfusion-associated graft-versus-host disease. Tradi-
tional approaches to reduce these events include
improved selection of blood donors and leukoreduction,
gamma-irradiation, and bacterial screening of blood
components.
Commercial technologies using ultraviolet light to
irradiate platelets in the presence of amotosalen or ribofla-
vin have been developed that inactivate pathogens and
abrogate leukocyte replication, preventing transfusion-
associated graft-versus-host disease.1,2 The safety of
pathogen-reduced platelets has been evaluated in several
randomized clinical trials3-9 and is supported by hemovi-
gilance data.10,11
Pathogen-reduction (PR) technologies provide an
opportunity to “raise the bar”12 of transfusion safety, not
only by reducing bacterial contamination and septic
transfusion reactions13 but especially in relation to recent
concerns of transfusion-transmissible infectious agents
such as Zika virus.14
Although these technologies for PR of platelets have
been evaluated independently using superiority3,6 and
noninferiority trial designs,4,5,7-9 the two methods have
not been tested concurrently in one country. A full tech-
nology assessment of these methodologies would provide
useful information about risk-based decision making for
blood safety.15,16
We report on the safety and efficacy of platelets
treated with the above-described PR technologies, which
were evaluated in parallel in the Italian Platelet Technolo-
gy Assessment Study. Our specific interest was to collect
local data useful for future evaluations of the cost effec-
tiveness of PR technologies and deliberations on their
mandatory versus voluntary use in our country. The main
objectives of the study were to determine the effectiveness
and safety of pathogen-reduced platelets in oncohematol-
ogy patients undergoing chemotherapy or allogeneic
hemopoietic stem cell transplantation.
MATERIALS AND METHODS
Study design
The Italian Platelet Technology Assessment Study was
designed as two independent, randomized controlled tri-
als (RCTs) conducted simultaneously in six hematological
centers in Italy to assess the effectiveness and safety of PR
versus non-PR platelets. The design of each RCT was iden-
tical with the exception of the PR technology used in the
treatment arms. Three sites evaluated Intercept platelets
(Cerus), and three other sites evaluated Mirasol platelets
(Terumo BCT). The study was approved by the
Institutional Review Board of the clinical coordination site
at Foundation Ca’ Granda Ospedale Maggiore Policlinico
(Milan) and was performed in agreement with the princi-
ples of the Declaration of Helsinki (Edinburgh, Scotland,
2000). A Data and Safety Monitoring Board monitored the
study for data quality and safety and operational issues.
Two formal interim analyses were prespecified to occur
after enrolment of 66 and 133 patients in each arm,
respectively. Formal stopping rules were not prespecified.
The study protocol and the case report forms are available
in the supporting information. The study was registered at
www.clinicaltrials.gov as National Clinical Trial NCT01642563.
Patients
Patients were eligible for the study if they were adults
(aged 18 years or older) with a hematological cancer
expected to require two or more platelet transfusions dur-
ing a single course of remission induction or consolida-
tion chemotherapy or during allogeneic hemopoietic stem
cell transplantation. Exclusion criteria included: patients
with promyelocytic leukemia, because of the high fre-
quency of coagulopathy and bleeding unrelated to platelet
count in this condition; patients who received previous
transfusions and had historical documentation of two or
more 1-hour posttransfusion platelet corrected count
increments (CCIs) below 5000/lL; and patients who had
anti-HLA antibodies on admission with greater than 20%
panel reactive antibodies. Patients could be enrolled only
once and gave written informed consent for participation.
Randomization and masking
There were two levels of randomization: sites and
patients. Sites were randomly allocated to the Intercept or
Mirasol trial by the administrative coordinating center
(Italian National Blood Center, National Institute of
Health, Rome). The treatment allocation schedule for
patients was prepared by the Italian National Blood Cen-
ter using a computer-generated assignment sequence
stratified by site and whether the patient was receiving
chemotherapy or allogeneic hemopoietic stem cell trans-
plantation. Patients were assigned using a 1:1 ratio to one
of the two study arms using random permuted blocks
with block size equal to 8. Patients were randomized at
the time of their first platelet transfusion request by the
local blood transfusion service staff using opaque enve-
lopes that contained the treatment assignment. Only the
study data manager and the local blood transfusion service
staff had knowledge of the patient’s randomization arm.
Procedures
Platelets were prepared from whole blood with the buffy-
coat method or were collected by apheresis, resuspended in
approximately 30% plasma and 70% platelet additive solu-
tion, and stored for a maximum of 5 days at 20 to 248C
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under constant agitation. Both PR and control platelets were
prepared by each of the six blood transfusion services partic-
ipating in the study. A platelet dose (total platelet count) was
determined in all platelet units at the time of production.
PR platelets were prepared according to manufac-
turers’ instructions using regularly maintained PR devi-
ces by staff from the local blood transfusion service.
Intersol or SPP1 and Intersol or Composol platelet additive
solutions were used for both PR and non-PR platelets in
centers that used the Intercept and Mirasol PR technolo-
gies, respectively. Each center used only one platelet addi-
tive solution throughout the study. PR platelets were not
gamma-irradiated or selected to be cytomegalovirus-
negative.
Standard platelets, PR platelets, and red blood cells
(RBCs) were leukoreduced prestorage with locally vali-
dated procedures compliant with the European Union
requirement of a final leukocyte count below 1 3 106
per unit. The clinical sites used a RBC transfusion trig-
ger of 80 g/L hemoglobin. Prophylactic platelet transfu-
sion triggers of 10 3 109/L and 20 3 109/L were used
for stable patients and for patients who had a rapid fall
of the platelet count, documented infection, and/or
body temperature greater than 388C, respectively. Non-
PR platelets and RBCs used in both the treatment and
control arms were gamma-irradiated and selected
based on cytomegalovirus serology according to clini-
cal indication.
Patient observation started on the day of the first
platelet transfusion and continued for 28 days or less if
the patient did not receive platelet transfusions for 7
days, was discharged, or died. Daily bleeding assess-
ments were performed by a local clinical investigator
blinded to the treatment allocation by patient interview,
clinical assessment, and chart review. A bleeding grade
was assigned according to World Health Organization
criteria17 and the system or organ affected. All bleeding
episodes occurring between daily evaluations, including
different grades and the system or organ affected, were
recorded. The clinical staff at each center was not
informed of patient allocation, and the local investi-
gators were instructed to perform bleeding assessments
at times different from platelet transfusion administra-
tion to avoid possible unblinding due to slight visible
differences in platelet products. Body temperature,
blood pressure, and heart rate were collected before
and after platelet transfusion. After each platelet trans-
fusion, patients were evaluated for adverse events (AEs)
that occurred in the next 24 hours. AEs were assessed
for relation to the platelet transfusion and graded for
clinical severity. Transfusions with AEs possibly, proba-
bly, or definitely related to platelet transfusion were
defined as transfusions with an acute reaction. Other
collected data included: blood product transfusion
data, routine laboratory test results, patient demo-
graphics, diagnosis and therapies, and baseline HLA
screening results. Regular audits were performed by an
independent monitor to ensure accuracy and quality of
data.
Outcomes
The primary endpoint was the percentage of patients
that developed one or more bleeding episodes of Grade
2 or greater.18 Grade 2 bleeding was defined as oropha-
ryngeal bleeding or epistaxis with total duration greater
than 30 minutes in the previous 24 hours, purpura with
a diameter greater than 1 inch, spontaneous hematomas
in deeper tissues, joint bleeding, melena, hematochezia,
hematemesis, gross or visible hematuria, abnormal vagi-
nal bleeding, hemoptysis, blood in bronchopulmonary
lavage or blood-tinged sputum, visible blood in body
cavity fluid, retinal bleeding without visual impairment,
lumbar puncture with blood (>5 RBCs/mL in cerebrospi-
nal fluid on microscopic analysis and nontraumatic tap,
no visible red color), and bleeding at invasive sites with
total duration greater than 1 hour in the previous 24
hours. Grade 3 bleeding was defined as any bleeding
that required RBC transfusion over routine transfusion
needs, grossly bloody body cavity fluids and organ dys-
function with symptoms, lumbar puncture with visible
red color in the absence of symptoms and nontraumatic
tap, or any bleeding associated with moderate hemody-
namic instability. Grade 4 bleeding was defined as fatal
bleeding from any source; retinal bleeding with visual
impairment; central nervous system symptoms with
nontraumatic, bloody lumbar puncture; central nervous
system bleeding on an imaging study; or any bleeding
associated with severe hemodynamic instability.
Secondary outcomes included: time to the episode of
Grade 2 or greater bleeding; number of days with Grade 2 or
greater bleeding; number of transfused platelets; proportion
of patients with acute transfusion reactions; posttransfusion
platelet count increments; proportion of patients developing
platelet transfusion refractoriness, defined as the detection
of 1-hour posttransfusion corrected platelet count
increments below 5000/mL after two consecutive ABO-
compatible, fresh (2 days old) platelet transfusions.
One-hour and 24-hour CCIs were determined using
the following formula:
Post2pre transfusion platelet count =lLð Þ x patient body surface area m2 
Platelets dose x 1011
 
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The patient’s body surface area was determined
according to DuBois and DuBois.19
Statistical analysis
Based on local historical data, it was estimated that the
frequency of Grade 2 or greater bleeding in the reference
group would be 20%. With a noninferiority margin of 11%,
which was considered appropriate in relation to the
expected benefits of PR, a one-sided Type I error of 0.025,
and power of 80%, 207 patients per arm in each trial (828
in total) were required. However, because of financial
restrictions, the study was closed before the planned sam-
ple size was reached.
The primary analysis was done on the intention-to-
treat (ITT) population, including 424 evaluable patients
who received at least one platelet transfusion. A prespeci-
fied per protocol (PP) analysis was done excluding all
treated and control patients who had received at least one
non-PR and PR platelet unit, respectively. A post-hoc sub-
group ITT analysis was carried out on patients with acute
myeloid leukemia (AML) in consideration of the higher
proportion of leukemic patients in the treatment arm of
the Intercept trial.
No imputation was done for missing data. Secondary
outcomes in treated and control patients were compared
by determining differences or ratios and their 95% confi-
dence intervals (CI) with no a priori hypothesis of nonin-
feriority, equivalence, or superiority.
The upper one-sided 97.5% confidence limit (UCL) of
the between-arm difference in the occurrence of the
primary endpoint was computed according to Santner
and Snell.20 The same approach was adopted to compute
two-sided 95% confidence limits of the between-arm
differences in the number of deceased or refractory
patients or patients who had transfusion reactions. In
case of inconsistency between exact test results and exact
confidence limits, continuity-adjusted chi-square test and
95% asymptotic confidence limits were adopted. Confi-
dence limits of the odds ratios for the number of days
with a leukocyte count less than 1.5 3 109/L (a proxy of
bone marrow depression selected post-hoc), the number
of days with Grade 2 or greater bleeding, and the number
of transfusion reactions were derived from a generalized
linear mixed model for binomial variates, using a logit link
function. Confidence limits of differences and ratios in the
number of platelet and RBC units transfused were derived
from a generalized linear model for Poisson variates using
an identity link-function for differences and a logarithmic
link-function for ratios. Confidence limits of the differ-
ences in the other secondary endpoints were derived from
an ordinary general linear model. Differences between
patients with and without Grade 2 or greater bleeding dur-
ing the study and the number of blood components used
were estimated with a two-factor general linear model
with interaction (arm, bleeding, arm 3 bleeding). All anal-
yses were carried out on a per-patient basis; that is,
patients were included in the models as random terms
within each arm, and the observations were included as
random terms within patient.21
Days to the occurrence of the first Grade 2 or greater
bleeding and to the onset of refractoriness were expressed
in terms of Kaplan-Meier survival curves, and between-
arm differences were tested with the log-rank test. Data
processing and statistical analyses were carried out with
SAS version 9.2 (SAS Institute, Inc.). A p value less than
0.05 was considered statistically significant.
RESULTS
Between October 20, 2010 and June 30, 2014, 360 and 246
patients were assessed for eligibility in the Intercept and
Mirasol trials, respectively. In the Intercept trial, 118
patients were randomized to the PR arm, and 119 were
randomized to the standard platelets arm. In the Mirasol
trial, 102 patients were randomized to receive PR platelets,
and 99 were randomized to receive standard platelets
(Fig. 1).
General characteristics of patients included in the ITT
analysis and the number of days with leukocyte count less
than 1.5 3 109/L are shown in Table 1. There was a higher
prevalence of patients with leukemia and of males in
treated versus control patients in the Intercept and
Mirasol trials, respectively.
Statistical significance of the differences between
arms in the ITT populations are reported in Table 2.
Descriptive statistics are reported in Tables 3 through 6.
The number of patients who had bleeding episodes
and the bleeding sites or organs are detailed in Table 3.
Because of the low statistical power caused by early study
termination, no conclusion was drawn about the nonin-
feriority of PR platelets, and the primary endpoint is
reported only for descriptive purposes. The absolute risk
differences of proportions of patients with Grade 2 or
greater bleeding in the treated versus control arms were
16.1% (UCL, 119.2%) and 14.1% (UCL, 118.5%) in the
Intercept and Mirasol trials, respectively (Table 2).
Proportions of patients who were free of Grade 2 or
greater bleeding during the study are reported in Fig. 2.
Differences between the treated and control arms were
not statistically significant.
Characteristics of blood components, duration of the
study, and the number of platelets and RBC units trans-
fused are shown in Table 4. More than 80% of the platelets
were transfused within 2 days of storage. Protocol viola-
tions related to the transfusion of non-PR platelets to
patients allocated to the treatment arm occurred in 2.8
and 6.4% of platelet transfusions in the Intercept and Mir-
asol trials, respectively, because of temporary nonavail-
ability of the specific product. Platelet counts in apheresis
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and buffy-coat–derived platelets were comparable in the
different arms and in compliance with local standards.
Centers that used the Intercept and Mirasol technologies
used buffy-coat–derived platelets in approximately 97 and
50% of transfusions, respectively. Table 2 shows that the
mean blood component use in treated patients versus
controls was 54% (95% CI, 36%-74%; Intercept) and 34%
(95% CI, 16%-54%; Mirasol) higher for platelet units, and
23% (95% CI, 8%-39%; Intercept) and 32% (95% CI, 10%-
57%; Mirasol) higher for RBC units. On average, patients
in the treated arms of the Intercept and Mirasol trials used
2.07 (95% CI, 0.82-3.51) and 1.17 (95% CI, 0.27-2.07) more
platelet units than patients in the control arms, respec-
tively (Table 2).
Pretransfusion and posttransfusion absolute platelet
counts, posttransfusion count increments, CCIs, and the
number of days between platelet transfusions are shown
in Table 5. Both 1-hour and 24-hour posttransfusion plate-
let count increments and CCIs in treated patients were
lower than the increments in controls. Differences
between the treated and control arms were statistically
significant with the exception of 1-hour CCIs in the
Intercept trial and 1-hour count increments in the Mirasol
trial (Table 2).
Time on study and the number of RBC and platelet
units given to patients with and without Grade 2 or greater
bleeding are shown in Table S1 (available as supporting
information in the online version of this paper). Blood
component use was statistically significantly increased in
patients with Grade 2 or greater bleeding, with the excep-
tion of platelet use in controls on the Mirasol trial. Occur-
rence of bleeding was associated with statistically
significant longer time on study in both treated and con-
trol patients.
Data from refractory patients are shown in Table
2, Table S2, and Fig. S1 (available as supporting infor-
mation in the online version of this paper). Refractori-
ness was significantly more frequent in recipients of
PR platelets versus controls (Intercept trial, 13.3 vs.
4.3%; Mirasol trial, 18.2 vs. 4.1%). Pretransfusion and
posttransfusion platelet counts before and after detec-
tion of refractoriness did not show clinically relevant
differences associated with treatment arm (Table S2,
available as supporting information in the online
Fig. 1. This flow diagram illustrates the progress through the study phases.
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TABLE 1. Characteristics of the study patients
Intercept trial Mirasol trial
Item PR platelets Standard platelets PR platelets Standard platelets
No. of enrolled patients 118 119 102 99
No. of patients included
in ITT analysis (%)
113 (95.8) 115 (96.6) 99 (97.1) 97 (98.0)
Male sex, no. (%) 68 (60.2) 68 (59.1) 67 (67.7) 50 (51.6)
Age: Median/range, years 53/18-85 53/19-76 56/20-82 54/22-76
Height: Median [IQR], cm 170 [160-174] 170 [164-175] 170 [165-176] 172 [163-178]
Body weight: Median [IQR], kg 73 [61-83] 73 [63-81] 70 [62-80] 72 [60-81]
Disease classification, no. (%)
Leukemia 84 (74.3) 69 (60.0) 72 (72.7) 69 (71.1)
Lymphoma 16 (14.2) 23 (20.0) 16 (16.2) 22 (22.7)
Other 13 (11.5) 23 (20.0) 11 (11.1) 6 (6.2)
Chemotherapy/allogeneic
transplantation
101/12 102/13 85/14 83/14
Total no. (%) of days with leukocyte
count <1.5 3 109/L/total no. of
days with complete blood count
562/789 (71.2) 471/598 (78.8) 474/543 (87.3) 358/409 (87.5)
Percentage of days with leukocyte
count <1.5 3 109/L, mean6SD
49.6625.7 42.6626.5 39.5627.4 38.3624.3
IQR5 interquartile range.
TABLE 2. ITT analysis: results of statistical analysis, reported as the difference (D), odds ratio (OR), or ratio (R)
between the treatment and control arms*
Item Intercept trial p Mirasol trial p
Primary outcome
Percentage of patients with
Grade 2 bleeding: D
16.1% (UCL, 119.2%) 0.1648 14.1% (UCL, 118.5%) 0.2489
Secondary outcomes
No. of days with
Grade 2 bleeding: OR
1.55 (0.67; 3.63) 0.3100 1.10 (0.44; 2.74) 0.8414
No. of days with leukocyte
count <1.5 3 109/L: OR
0.82 (0.48; 1.39) 0.4544 1.00 (0.55; 1.84) 0.9881
No. of days on platelet support: D 11.88 (10.04; 13.72) 0.0452 11.45 (10.11; 12.80) 0.0342
No. of platelet units transfused: R 1.54 (1.36; 1.74) < 0.0001 1.34 (1.16; 1.54) < 0.0001
No. of platelet units transfused: D 12.07 (11.49; 12.64) < 0.0001 11.17 (10.61; 11.73) < 0.0001
No. of platelets transfused, 3 109/L: D 1556 (1172; 1941) 0.0047 1399 (1118; 1681) 0.0057
No. of RBC units transfused: R 1.23 (1.08; 1.39) 0.0015 1.32 (1.10; 1.57) 0.0024
No. of RBC units transfused: D 10.87 (10.34; 11.41) 0.0014 10.69 (10.25; 11.14) 0.0023
1-Hour posttransfusion platelet
count increment, 3 109/L: D
24.42 (27.80; 21.04) 0.0105 28.91 (218.94; 11.11) 0.0810
24-Hour posttransfusion platelet
count increment, 3 109/L: D
27.06 (210.37; 23.75) < 0.0001 24.28 (27.47; 21.08) 0.0090
1-Hour posttransfusion corrected
platelet count increment: D
22004 (24045; 138) 0.0543 25282 (210,436; 2128) 0.0446
24-Hour posttransfusion corrected
platelet count increment: D
23066 (24926; 21206) 0.0014 22554 (24212; 2896) 0.0027
Percentage of patients with
nonhemolytic, febrile transfusion
reactions to platelets: D
12.82 (29.90; 115.96) 0.5310 21.22 (215.44; 112.55) 0.8132
Percentage of patients with allergic
transfusion reactions to platelets: D
20.73 (213.56; 112.48) 1.0000 10.99 (213.24; 115.11) 1.0000
No. of platelet transfusions followed by
nonhemolytic, febrile reactions: OR
0.76 (0.35; 1.64) 0.4842 0.76 (0.29; 2.10) 0.6013
No. of platelet transfusions followed by
allergic reactions: OR
0.63 (0.24; 1.63) 0.3406 1.50 (0.13; 17.16) 0.7435
Percentage of refractory patients: D† 18.93 (11.64; 116.21) 0.0317 114.06 (15.49; 122.62) 0.0038
Percentage of patients who died: D 26.01 (218.80; 17.26) 0.1286 14.00 (210.30; 117.98) 0.2790
* Data in parentheses indicate the upper one-sided 97.5% confidence limit (UCL) for primary outcome and the two-sided 95% confidence lim-
its for secondary outcomes.
† Adjusted chi-square and asymptotic confidence limits are shown.
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version of this paper), suggesting that refractoriness
was occasional and transitory.
Transfusion reactions, complete remission in chemo-
therapy recipients, and frequency and causes of death are
reported in Table 6. Differences between treated and con-
trol patients were not statistically significant (Table 2).
Unexpected reactions and AEs were not reported. Hemor-
rhagic shock was the cause of death in one recipient of PR
platelets who had a platelet count of 26 3 109/L on the
day of death. There was no evidence that the cause of
death was related to platelet transfusion.
The numbers of transfusion reactions to RBCs are
provided in Table S3 (available as supporting information
in the online version of this paper).
Results of the PP analysis are shown in Tables S4
through S7 (available as supporting information in the
online version of this paper). Results of the post-hoc ITT
analysis of patients with AML are provided in Tables S8
through S12 (available as supporting information in the
online version of this paper).
The primary ITT, PP, and post-hoc ITT analyses in
patients with AML yielded concordant statistical signifi-
cances for differences and ratios of the number of trans-
fused platelet units and for absolute and corrected
posttransfusion platelet count increments at 24 hours.
DISCUSSION
We compared the safety and efficacy of PR versus stan-
dard platelets in two parallel RCTs to contribute local data
to a national program of transfusion technology assess-
ment designed to assess the costs and benefits of two
commercial PR technologies.
The study closure before completion of the planned
sample size, which was not related to safety issues, pre-
vented us from drawing conclusions on PR platelets non-
inferiority. PR platelet recipients displayed a numerically
higher but not statistically significantly increased frequen-
cy of the composite outcome of mild to severe bleeding,
the latter consisting mainly of mild bleeding events. Fur-
thermore, no evidence of unexpected transfusion reac-
tions or AEs was reported. In both trials, per patient
analyses showed statistically significant reductions in
posttransfusion platelet count increments and increased
use of platelets and RBCs in PR platelet recipients.
Although our study was not designed to directly compare
the two commercial PR technologies, we noted that their
performance in relation to local standard platelets was
similar.
Other than the reassuring evidence that the use of PR
platelets was not associated with unexpected reactions or
TABLE 3. ITT analysis: number (%) of patients and days with Grade 2 or greater bleeding episodes and bleeding
site/organ calculated as the number of patients and days with available bleeding report forms
Item
Intercept trial Mirasol trial
PR platelets Standard platelets PR platelets Standard platelets
No./total no. (%) of patients with
Grade 2 bleeding episodes
24/109 (22.0) 17/107 (15.9) 13/97 (13.4) 9/97 (9.3)
Reported on 1 day 11 6 7 3
Reported on 2 days* 2 3 2 2
Reported on 3 days* 1 3 1 1
Reported on 4 days* 2 2 1 0
Reported on >4 days* 8 3 2 3
No. (%) of patients with
Grade 3 bleeding episodes
0 1 (0.9) 0 0
No. (%) of patients with
Grade 4 bleeding episodes
2 (1.8) 0 1 (1.0) 2 (2.1)
No./total no. (%) of days with
Grade 2 bleeding
116/1266 (9.2) 61/1119 (5.5) 30/1118 (2.7) 39/1065 (3.7)
Mean6SD no. of days with
Grade 2 bleeding per patient
with Grade 2 bleeding
4.836 5.98 3.5964.03 2.316 1.93 4.3364.18
No. (%) of patients; no. (%) of
days with grade 2 bleeding
by site/organ
Oral, nasal 14 (12.8); 28 (2.2) 8 (7.5); 15 (1.3) 4 (4.1); 5 (0.4) 5 (5.2); 9 (0.8)
Skin, soft tissue, musculoskeletal 16 (14.7); 90 (7.1) 8 (7.5); 29 (2.6) 5 (5.2); 8 (0.7) 3 (3.1); 19 (1.8)
Gastrointestinal, genitourinary,
gynecologic
10 (9.2)†; 38 (3.0) 6 (5.6); 27 (2.4) 5 (5.2); 14 (1.3) 2 (2.1); 3 (0.3)
Pulmonary 0 1 (0.9); 4 (0.4) 1 (1.0); 1 (0.1) 1 (1.0); 1 (0.1)
Body cavity 0 0 0 0
Neurologic 1 (0.9); 6 (0.5) 0 1 (1.0); 5 (0.4) 2 (2.1); 20 (1.9)
Invasive sites 1 (0.9); 2 (0.2) 0 0 0
Hemodynamic instability 1 (0.9); 1 (0.1) 1 (0.9); 1 (0.1) 0 0
* These episodes were reported on consecutive or nonconsecutive days.
† In one patient who died of hemorrhagic shock, the last platelet count available before death was 26 3 109/L.
PATHOGEN-REDUCED PLATELETS
Volume 57, May 2017 TRANSFUSION 1177
severe hemorrhagic events with significantly greater fre-
quency than those observed in recipients of standard pla-
telets, our data confirm lower posttransfusion platelet
count increments in PR platelet recipients versus controls,
as reported in other studies. Our data suggest that lower
increments were a possible cause of a slight shortening of
the platelet transfusion interval, in turn translating into a
mean of one or two more platelet units given to PR plate-
let recipients versus controls. Although this absolute
mean increment per patient may appear small, it corre-
sponded to 54 and 34% greater platelet use in the recipi-
ents of Intercept-treated and Mirasol-treated platelets,
respectively.
We have no clear interpretation for the increased RBC
use in the treatment arms of both trials, because most
bleeding episodes detected in the treatment arms were
World Health Organization Grade 2 or lower, which usual-
ly are considered of little clinical significance. However, it
is possible that repeated minor bleeding may have
required greater RBC support in some patients.
The finding of significantly increased proportions of
patients who were refractory to platelet support in the
treatment arms of both trials was not unexpected, because
this was clearly associated with significantly inferior
posttransfusion platelet count increments. This deficiency
could be corrected by increasing the platelet dose in units
undergoing PR, as performed in two RCTs.3,9 Additional
studies are in progress to investigate the presence of anti-
HLA antibodies in the serum of refractory patients.
Operationally, we collected reassuring evidence that
the additional step of PR along with routine procedures of
platelet preparation was not associated with undesirable
prolongation of platelet storage and transfusion of older
platelets, as supported by comparable platelet ages at
transfusion in the treatment and control arms. Moreover,
staff training, qualification, and maintenance of the PR
devices did not outline particular problems or difficulties.
Our findings should be considered within the broad
context of the results from other RCTs that have tested PR
versus standard platelets.3-9 Their methodological similar-
ities and differences have been carefully analyzed by Cook
and Heddle.22
Similar to our study, most trials performed with the
Intercept technology evaluated multiple transfusions of
PR platelets obtained by apheresis or from buffy-coat
pools, suspended in a mixture of plasma and commercial-
ly available platelet-additive solutions, and stored for 1 to
5 days.3-7 Control platelets were stored in plasma/platelet
additive solutions3,7,9 or 100% plasma.4,6,7 Two studies
extended platelet storage to 7 days,7,9 and one study limit-
ed the evaluation to one transfusion per patient receiving
PR or standard platelets stored for 6 or 7 days.9 An
increase in the platelet dose to account for expected loss
due to pathogen reduction was performed only in one
center that participated in the euroSPRITE trial3 and in
the study reported by Lozano and colleagues.9 The robust-
ness and generalizability of the conclusions of these trials
vary not only in relation to many methodological differ-
ences but also in relation to their sample size, ranging
from 436 to 6454 patients. Although most trials used a sur-
rogate marker of clinical efficacy, such as the
posttransfusion platelet count increment, only the
SPRINT trial,4 similar to our study, selected bleeding, that
is, a “patient-based outcome”22 as the primary outcome.
Despite several existing similarities, a direct comparison
of the results from our Intercept trial with those of the
above-described studies3-7,9 is hampered by methodologi-
cal differences. First, mean platelet age at transfusion was
less than 2 days in our trial, whereas it was 3 or 4 days in
four studies,3,4,6,7 and 6 or 7 days in one9 previously pub-
lished Intercept RCT. Second, policies for platelet gamma-
irradiation had significant variations among the RCTs,
because gamma-irradiation was not used for PR platelet
Fig. 2. ITT analysis. The proportions of patients who were
free of Grade 2 or greater bleeding in the (A) Intercept and
(B) Mirasol trials are shown. Thin solid and dashed lines
represent 95% confidence bands in treated and control
patients, respectively.
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recipients in our study and in euroSPRITE,3 but it was par-
tially6,7,9 or systematically4 performed in others.
Despite the methodological differences, it is worth
noting that all Intercept trials show highly concordant
decrements of mean posttransfusion platelet CCI with PR
platelets compared with control platelets. More specifi-
cally, mean 24-hour CCIs with PR platelets were 30.2,3
33.7,4 29.8,6 31.9,7 30.0,9 and 33.5% (this study) lower com-
pared with control platelet CCIs. This finding, which also
was confirmed in our study using relatively fresher plate-
lets, may be clinically and economically relevant, because
lower posttransfusion platelet counts detected on the day
after transfusion may cause increased platelet use. Lower
posttransfusion platelet count increments in PR recipients
TABLE 4. ITT analysis: characteristics of blood components, duration of study, number of platelets and RBC units
transfused (total and per patient)*
Item
Intercept trial Mirasol trial
PR platelets Standard platelets PR platelets Standard platelets
Total no. of adult platelet doses 667 441 457 334
Transfusions received within 2 days
of storage/no. with data
596/665 (89.6%) 358/434 (82.5%) 367/456 (80.5%) 262/334 (78.4%)
ABO compatible/no. with data 552/631 (87.5%) 309/346 (89.3%) 357/441 (81.0%) 123/147 (83.7%)†
Prepared by apheresis/no. with data 4/667 (0.6%) 12/441 (2.7%) 214/457 (46.8%) 174/324 (53.7%)
Leukoreduced/no. with data 666/667 (99.9%) 439/441 (99.6%) 457/457 (100%) 334/334 (100%)
Gamma irradiated/no. with data 3/667 (0.5%) 243/441 (55.1%) 13/457 (2.8%) 195/334 (58.4%)
Pathogen reduced/no. with data 648/667 (97.2%) 9/441 (2.3%) 428/457 (93.6%) 0/334 (0%)
Platelet content in apheresis platelets,
3 109 [no. with data]
3516 95 [4] 3076 68 [11] 331645 [214] 323 657 [174]
Platelet content in pooled platelets,
3 109 [no. with data]
292635 [654] 309643 [385] 325670 [238] 328658 [143]
Days of storage of platelets at
transfusion [no. with data]
1.2960.79 [665] 1.4860.92 [434] 1.6661.04 [457] 1.736 0.96 [334]
No. of leukoreduced RBC
units/no. with data
533/533 (100%) 434/442 (98.2%) 275/286 (96.2%) 204/213 (95.8%)
No. of gamma-irradiated RBC
units/no. with data
204/533 (38.3%) 261/442 (59.0%) 273/286 (95.5%) 204/213 (95.8%)
No. of days from first platelet transfusion
to study end (total)
15.7566.94 (1780) 14.296 6.32 (1643) 13.9064.97 (1376) 12.976 4.71 [1258]
No. of days from first to last
platelet transfusion (total)
9.9668.23 (1126) 8.046 7.44 (925) 7.6265.50 (754) 6.236 4.84 [604]
No. of days on platelet support (total)‡ 9.0467.56 (1022) 7.176 6.50 (824) 7.0265.47 (695) 5.576 3.92 [540]
No. of adult platelet doses
transfused (total)
5.9065.84 (667) 3.836 3.40 (441) 4.6263.96 (457) 3.446 2.13 [334]
No. of platelets transfused, 3 109 17516 1674 119461093 15156 1222 11156702
No. of RBC units transfused (total) 4.726 5.0 (533) 3.8464.0 (442) 2.8962.90 (286) 2.2062.0 (213)
* Data are given as numbers, percentages, and means 6SD.
† Data were missing from two centers in the Mirasol trial.
‡ The sum of days is indicated from the first to last platelet transfusion with the exclusion of inter-transfusion intervals 5 days or longer.
TABLE 5. ITT analysis: pretransfusion and posttransfusion platelet counts (3 109/L), posttransfusion platelet count
increments, CCIs and number of days between platelet transfusions
Mean6SD (no. with data)
Item
Intercept trial Mirasol trial
PR platelets Standard platelets PR platelets Standard platelets
Pretransfusion platelet count 14.46 7.4 (661) 14.167.7 (439) 10.263.6 (456) 11.16 4.6 (326)
1-Hour posttransfusion
platelet count
29.96 14.0 (573) 33.6616.7 (357) 33.9629.4 (426) 43.26 35.8 (306)
24-Hour posttransfusion
platelet count
24.56 11.9 (646) 31.4616.8 (423) 21.8610.2 (449) 26.96 13.1 (320)
1-Hour posttransfusion
count increment (CI)
15.56 9.2 (571) 19.9612.9 (356) 23.7629.8 (426) 32.66 38.0 (304)
24-Hour posttransfusion CI 10.16 8.0 (644) 17.2614.1 (422) 11.569.1 (449) 15.86 12.5 (320)
1-Hour posttransfusion
corrected CI (CCI)
9,3876 5,263 (554) 11,39167,037 (313) 12,357614,592 (423) 17,6396 19,843 (304)
24-Hour posttransfusion CCI 6,0876 4,512 (621) 9,15366,703 (363) 6,05164,484 (445) 8,6056 6,696 (319)
No. of days between
platelet transfusions
2.036 0.76 2.4960.82 1.9860.88 2.146 0.86
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were associated with 54, 36, 35, and 12% higher mean
numbers of platelet transfusions per patient in our Inter-
cept trial, the euroSPRITE trial,3 the SPRINT trial,4 and the
HOVON7 trial, respectively. Despite lower posttransfusion
platelet count increments, an opposite finding of 20%
lower platelet use in the PR arm was reported by Janetzko
and coworkers6 in a small RCT with 22 PR platelet recipi-
ents and 21 controls, most of whom underwent autolo-
gous or allogeneic hemopoietic stem cell transplantation.
Less extensive published information is available on
the clinical effectiveness of PR platelets prepared with the
Mirasol technology. In total, 118 patients were random-
ized to receive PR or standard platelets in a noninferiority
RCT carried out in France.8 That study showed mean
1-hour posttransfusion CCIs (primary outcome) equal to
11,725 and 16,939 in recipients of PR platelets and stan-
dard platelets, respectively, corresponding to a 30.8%
reduction in PR platelet recipients. This reduction is very
similar to the 30% reduction of mean 1-hour CCI with PR
platelets observed in our Mirasol trial. The French study
reported a higher median number of on-protocol platelet
transfusions in PR versus standard platelet recipients
within the 28-day treatment period (4.5 vs. 3.0 respective-
ly; i.e., 50% greater in PR recipients). However, although
the authors noted that several study limitations caused
difficulties in the analysis of overall blood product
utilization, they reported no significant differences
between the treatment and control arms. The authors
concluded that the study failed to show noninferiority of
PR platelets and that more studies were required to deter-
mine whether the lower CCI observed with PR platelets
“translates into an increased risk of bleeding.”8
The data described above provide strong evidence of
lower posttransfusion platelet count increments with PR
platelets compared with standard platelets. This decre-
ment is also supported by our finding that both technolo-
gies were tested with relatively fresher platelets compared
with the other published RCTs.
Despite the lower posttransfusion platelet count
increments, PR platelets prepared with both technologies
have a high safety and efficacy record,3-11,23-26 because the
frequency and type of AEs and the risk and type of bleed-
ing reported in the literature and documented in our
study did not appear to differ between PR and standard
platelets.
Considering the economic restrictions that affect
health systems in many jurisdictions, the increased mar-
gin of microbiological and immunological safety of PR
platelets must be balanced with the cost of the procedures
and with the possibility that lower posttransfusion platelet
count increments generate increased blood component
utilization. In this regard, it is encouraging to note that a
TABLE 6. ITT analysis: transfusion reactions to platelets, remission in chemotherapy recipients, frequency, and
causes of death*
Item
Intercept trial Mirasol trial
PR platelets Standard platelets PR platelets Standard platelets
No./total no. (%) of platelet transfusions
with premedication
221/667 (33.1) 138/441 (31.3) 5/457 (1.1)† 34/334 (10.2)‡
No. (%) of patients with nonhemolytic,
febrile transfusion reactions
14 (12.4) 11 (9.6) 9 (9.1) 10 (10.3)
No. (%) of patients with allergic
transfusion reactions
9 (8.0) 10 (8.7) 2 (2.0) 1 (1.0)
No. (%) of nonhemolytic, febrile
transfusion reactions
15 (2.2) 13 (2.9) 18 (3.9) 18 (5.4)
No. (%) of allergic transfusion reactions 11 (1.6) 12 (2.7) 2 (0.4) 1 (0.3)
No. of patients with other transfusion
reactions [no. of reactions]
1 [1] 2 [4] 1 [1] 1 [1]
Remission in chemotherapy recipients:
complete/partial/refractory/not
available, no. of patients
40/31/18/12 40/26/20/16 15/34/2/34 15/33/4/31
No. of patients who died (%) 5 (4.4) 12 (10.4) 6 (6.1) 2 (2.1)
Cause of death
Hemorrhagic shock 1 0 0 0
Septic shock 2 0 1 0
Pulmonary insufficiency 1 1 0 0
Cardiac failure 1 3 2 2
Stroke 0 2 0 0
Disease progression 0 3 1 0
Hepatic failure 0 0 1 0
Not recorded 0 3 1 0
* No cases of hemolytic transfusion reactions, transfusion-related acute lung injury, transfusion-associated circulatory overload, transfusion-
associated graft-versus-host disease, or posttransfusion reactions were reported. Other reactions included chills and headache.
† Five patients received five transfusions.
‡ Eight patients received 34 transfusions.
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careful, retrospective analysis carried out in Belgium did
not disclose an “adverse impact on blood component use
during a 3-year observation period of routine practice” of
Intercept-treated platelets.27 Further independent studies
will be useful to corroborate this finding. Moreover, care-
ful analyses of selected recipient types in different settings
should be done using several methodological approaches
to economic evaluations related to the implementation of
PR platelets that have been reported in the literature.28-34
In parallel, strategies could be developed to investigate
public acceptability of PR technologies.35
In conclusion, our findings provide additional evi-
dence—in the first study to test both commercial technolo-
gies with a unique protocol—on the clinical safety and
efficacy of non-gamma–irradiated PR platelets in a large
group of thrombocytopenic adult patients with hematologic
cancers who received prophylactic transfusion. This evi-
dence, together with previously reported results from the
clinical trials that used the Intercept and Mirasol technolo-
gies, could be used by blood transfusion regulatory bodies
in charge of deciding whether the use of PR will remain vol-
untary or should become mandatory. Not only may this
decision be particularly urgent in light of the recent Zika
epidemic and possible additional future threats to blood
transfusion safety, but it also may become warranted in
view of the promising reports of laboratory studies and clin-
ical trials on pathogen-reduced RBCs and whole blood.36,37
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Fig. S1A. ITT analysis: proportion of nonrefractory
patients in the Intercept trial.
Fig. S1B. ITT analysis: proportion of nonrefractory
patients in the Mirasol trial.
Table S1. ITT analysis: time on study (no. of days) and the
number of blood components used in patients with (B)
and without (NB) 2 grade or greater bleeding. Data are
given as mean (SD) and differences (95% CI) between B
and NB patients. Interaction term was statistically signifi-
cant for the number of platelet units in Mirasol trial only.
Table S2. ITT analysis: data from refractory patients.
Data are given as percentage, mean (SD), or median
[range]. n.d.5not determined.
Table S3. ITT analysis: transfusion reactions to red
blood cells. No cases of transfusion-related acute lung
injury, circulatory overload, graft-versus-host disease, or
posttransfusion purpura were reported.
Table S4. Number of off-protocol and total platelet
units transfused to patients included in the ITT analysis
and excluded from the per protocol (PP) analysis of the
Intercept trial. Each row identifies one patient.
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Table S5. Number of off-protocol and total platelet
units transfused to patients included in the ITT analysis
and excluded from the PP analysis of the Mirasol trial.
Each row identifies one patient.
Table S6. PP analysis: the number of patients in each
study arm; percentage of days with leukocyte counts
less than 1.5 3 109/L; number (%) of patients and days
with grade 2 or greater bleeding; patients with nonhe-
molytic, febrile, and allergic transfusion reactions; and
refractory and deceased patients.
Table S7. PP analysis: results of statistical analysis,
reported as the difference (D), odds ratio (OR), or ratio
(R) between the treatment and control arms and their
upper one-sided 97.5% confidence limits (UCL) for pri-
mary outcome and two-sided 95% confidence limits for
secondary outcomes.
Table S8. ITT analysis: characteristics of patients with
AML. Data are given as mean (SD).
Table S9. ITT analysis: results of statistical analysis of
patients with AML reported as the difference (D), odds
ratio (OR), or ratio (R) between the treatment and con-
trol arms and their upper one-sided 97.5% confidence
limits (UCL) for primary outcome, and two-sided 95%
confidence limits for secondary outcomes.
Table S10. ITT analysis: number (%) of patients with
AML and days with grade 2 or greater bleeding epi-
sodes, calculated based on the number of patients and
days with available bleeding report forms.
IQR5 interquartile range.
Table S11. ITT analysis: duration of study and the num-
ber of platelets and RBC units received via transfusion
by patients with AML. Data are given as mean (SD) and
[total].
Table S12. ITT analysis: pretransfusion and
posttransfusion platelet counts (3 109/L),
posttransfusion platelet CIs, CCIs, and number of days
between platelet transfusions in patients with AML.
Data are given as mean (SD).
Study protocol
Case report forms
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